Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lexaria Bioscience (LEXX) Revenue (2017 - 2025)

Lexaria Bioscience's Revenue history spans 9 years, with the latest figure at $174000.0 for Q3 2025.

  • For Q3 2025, Revenue rose 107.14% year-over-year to $174000.0; the TTM value through Nov 2025 reached $522000.0, up 5.05%, while the annual FY2025 figure was $705923.0, 52.05% up from the prior year.
  • Revenue for Q3 2025 was $174000.0 at Lexaria Bioscience, roughly flat from $174000.0 in the prior quarter.
  • Across five years, Revenue topped out at $17.5 million in Q1 2022 and bottomed at -$17.4 million in Q2 2022.
  • The 5-year median for Revenue is $145000.0 (2024), against an average of $440082.1.
  • The largest annual shift saw Revenue skyrocketed 9758.39% in 2021 before it plummeted 8611.31% in 2022.
  • A 5-year view of Revenue shows it stood at $13880.0 in 2021, then surged by 604.14% to $97735.0 in 2022, then tumbled by 94.49% to $5388.0 in 2023, then soared by 3313.57% to $183923.0 in 2024, then fell by 5.4% to $174000.0 in 2025.
  • Per Business Quant, the three most recent readings for LEXX's Revenue are $174000.0 (Q3 2025), $174000.0 (Q2 2025), and $174000.0 (Q1 2025).